Navigation Links
EMIT Corporation Receives FDA 510(k) Clearance for HypothermX™ Blood and Fluid Warmer.

HOUSTON, May 26 2011 /PRNewswire/ -- EMIT Corporation announced today that it has received U.S. Food and Drug Administration 510(k) clearance to market the HypothermX™ HX100 device.  The HypothermX™ HX100 device is a patent protected portable fluid warming device designed to warm intravenous fluids, blood or blood products infused into a patient to prevent or treat trauma, environmental, procedure related, or induced hypothermia.  Heating is accomplished via a flameless hydrocarbon combustion process.  

"HypothermX HX100 is the first truly light weight (< 3.0 lbs), portable, long-term (>4 hours continuous use) solution to offer actual therapeutic warming in the field for injured patients.  HypothermX HX100 is capable of  warming up to 5 liters of saline introduced at 15 degrees C and 15 units of packed red blood cells  introduced at 5 degrees C to 38 degrees C +/- 3 degrees C with an infusion rate between 50 ml/min and 200 ml/min and ambient conditions between 0 degrees C and 40 degrees C.  The system has numerous safety features and provides the user with the ability to temporarily silence alarms based on operational needs," stated Mr. Sheldon, EMIT Corporation Founder, Chairman & CEO.   

"Our market clearance represents a significant milestone for the company and we will begin an aggressive sales and marketing campaign in the military and civilian market sectors this quarter," said Mr. Sheldon Mr. Sheldon went on to say that "hypothermia continues to plague the military and civilian first responder markets and our device will result in life saving interventions at the point of injury."

About EMIT Corporation

EMIT Corporation is focused on the design, development, manufacture, and sale of devices and related products for the treatment and prevention of hypothermia.  The HypothermX™ HX100 and ancillary products were invented by Charles Cox, Jr., MD and Brijesh Gill, MD and exclusively licensed from The University of Texas Health Science Center at Houston and The University of Texas at Austin following nearly $4.0 million of research and development funding provided by the United States Army Telemedicine and Advanced Technology Research Center.  EMIT Corporation raised an additional $2.4 million from CitareTx Investment Partners, a Texas based medical device investment fund and business incubator, also founded and managed by Mr. Sheldon.  

Contact: Jeffery J. Sheldon - Founder, Chairman & CEO, EMIT Corporation, +1-281-984-7355, , or fax, +1-281-984-7374, or mobile, +1-832-455-3173,

SOURCE EMIT Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Statement From Volcano Corporation on Latest St. Jude Lawsuit
2. Celladon Corporation Announces MYDICAR® Enzyme Replacement Therapy for Advanced Heart Failure Provides Sustained Reduction in Clinical Events in Patients for 18 Months Compared with Placebo
3. Gumz to Retire as President and CEO of Olympus Corporation of the Americas
4. Medication Delivery Innovator Baxa Corporation Offers Best Practices for Administering Over-the-Counter Liquid Medicine to Babies and Toddlers
5. Families of Spinal Muscular Atrophy Announces Repligen Corporation Receives FDA Approval to Begin Phase I Clinical Trial in SMA
6. TechPrecision Corporation Receives $1.6 Million in New Orders from Existing Customers
7. SenSage Named Cerner Corporations Accelerate Partner of the Year
8. Boston Scientific Announces Favorable Jury Verdict Against Cordis Corporation in Stent Patent Litigation
9. Henry Schein Ranks #317 in 2011 Fortune 500 Ranking of Americas Largest Corporations
10. Omeros Corporation Reports First Quarter 2011 Financial Results
11. Vista Partners Initiates Coverage on Helix BioPharma Corporation; Target Price $6.20
Post Your Comments:
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... the "Pharmaceutical Excipients Market by Type (Organic Chemical ... Preservative), Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast ... The global pharmaceutical excipients ... 2021 at a CAGR of 6.1% in the forecast ...
(Date:6/23/2016)... June 23, 2016 Capricor ... ), a biotechnology company focused on the discovery, ... that patient enrollment in its ongoing randomized HOPE-Duchenne ... exceeded 50% of its 24-patient target. Capricor expects ... third quarter of 2016, and to report top ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 If ... Leaders Scholarship is any indication, the future is in ... at by the Diabetes Scholars Foundation ... the way of academic and community service excellence. ... since 2012, and continues to advocate for people with ...
Breaking Medicine Technology:
(Date:6/26/2016)... Michigan (PRWEB) , ... June 26, 2016 , ... ... to fertility once they have been diagnosed with endometriosis. These women need a ... they also require a comprehensive approach that can help for preservation of fertility ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, ... Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. ... skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users ... - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 ... Pro X . Simply select a ProHand generator and drag it above media or ...
(Date:6/25/2016)... Long Beach, CA (PRWEB) , ... June 25, 2016 , ... ... from UCLA with Magna Cum Laude and his M.D from the David Geffen School ... San Diego and returned to Los Angeles to complete his fellowship in hematology/oncology at ...
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of ... recognition of their exemplary accomplishments in worksite health promotion. , The Wellness at Work ... Symposium at the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses ...
Breaking Medicine News(10 mins):